ENTAEnanta Pharmaceuticals, Inc.
Price
+9.2%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, a flag to check, demanding price, growth steady, the market against it.
Charts
As reported to the SEC, without any scoring.
Enanta Pharmaceuticals, Inc. (ENTA) reported revenue of $14M in Q3 2026 (quarter ended Jun 30, 2026), down 22% from the same quarter a year earlier. That came with net loss of $20M. For the full year FY2025, revenue was $65M (−3.4% year on year) and net income −$82M. The next results filing is expected around Nov 16, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026.Earnings release · press release
- Jul 2, 2026On July 2, 2026, Enanta Pharmaceuticals, Inc. (the “Corporation”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Corporation may offer and sell shares (the “Shares”) of its common stock, $0.01 par value per share (“Common …Material agreement entered · Form 8-K
- Jun 23, 2026As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the “’953 …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.